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Abstract
Introduction—Reimbursement for dual energy x-ray absorptiometry (DXA) scans in the 
outpatient setting has declined significantly since 2006. Research through 2011 has suggested 
reimbursement reductions for DXA scans have corresponded with an overall decreased utilization 
of DXA. This study updates utilization estimates for DXAs through 2012 in patients with 
commercial insurance and compares DXA rates before and after reimbursement changes.
Methods—We evaluated DXA utilization for women age 50–64 from Marketscan Commercial 
Claims and Encounter database between January 2006 and December 2012 based on CPT codes. 
We estimated utilization rates per 1,000 person years. We also employed segmented regression 
analysis of monthly rates to evaluate the change in utilization rates after a proposed 
reimbursement reduction in July 2009.
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Results—In women aged 50–64; 451,656 DXAs were performed in 2006, a rate of 144 DXAs 
per 1,000 person years. This rate increased to 149 DXAs per 1,000 person years in 2009 before 
decreasing to 110 DXAs per 1,000 person years or 667,982 scans in 2012. DXA utilization 
increased by 2.24 per 1,000 person years until July 2009 then declined by 12.98 DXAs per 1,000 
persons, resulting in 37.5 DXAs per person year fewer performed in 2012 compared to 2006.
Conclusion—Since July 2009 a significant decline in DXA utilization occurred in a younger 
postmenopausal commercially insured population. This decline corresponds with a time period of 
reductions in Medicare DXA reimbursement.
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Bone mineral density measurement using dual energy x-ray absorptiometry (DXA) is the 
most common method for diagnosing osteoporosis and identifying patients with low bone 
mass at risk for fractures.(1, 2) In 2010, 10.3 million US men and women ≥50 were estimated 
to have osteoporosis, with 43.1 million having low bone mass.(3) A 2004 systematic review 
of studies investigating the use of DXA in patients with fragility fractures reported a testing 
rate of less than 32% in 14 of 16 studies referenced, indicating a low rate of testing even in a 
population at a high risk for fracture.(4)
To standardize coverage and costs of DXA screening nationwide, the 1998 Bone Mass 
Measurement Act provided Medicare Part B coverage of DXAs up to every two years for 
beneficiaries with specific conditions (including all post-menopausal women) older than age 
65.(5) However to control Medicare expenditures, reimbursement for DXA and other 
outpatient imaging services were reduced under the Deficit Reduction Act of 2005. The act 
reduced DXA reimbursement to $55 in 2010, well below the estimated median cost of 
$134.13 in 2007 for outpatient DXAs and significantly less than the mean reimbursement of 
$139 in 2006.(6, 7) On July 1, 2009 the Centers of Medicare & Medicaid Services (CMS) in 
a yearly revision to the Physician Fee Schedule (CMS-1413-P) reduced reimbursement for 
resource value units associated with DXA which reduced reimbursement to $45 beginning 
in 2010.(8, 9) The CMS-1413 changes were implemented, however their effect was not felt in 
2010 or 2011 as the Affordable Care Act (ACA) temporarily increased reimbursement for 
these two years.(10) But on March 1, 2012 the full reimbursement cuts were actualized 
resulting in a reported mean reimbursement of $56 per DXA test.(10)
Changes in DXA reimbursement have had the potential to significantly affect utilization in 
both the Medicare and commercially insured population. Although reimbursement 
reductions targeted the Medicare (aged ≥65) population, fewer outpatient centers were 
reported to offer DXAs by 2009, which could also affect DXA utilization in the 
commercially insured population.(11) Studies of DXA utilization through 2011 have been 
undertaken in both the Medicare and commercially insured population with differing results. 
In the Medicare fee-for-service population DXA utilization has been shown to increase from 
2002 until 2008 or 2009 depending on study before small declines in 2010 and 
2011.(6, 11, 12) In patients with commercial insurance, decreases between 2005 and 2008 
were reported for patients with Medicare Supplementary Insurance and increases between 
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2000 and 2009 for commercially insured patients less than age 64.(13, 14) Overall, and based 
on these reports that describe a diverse population including Medicare and/or commercially 
insured patients and covering time periods wherein reimbursement cuts were being phased 
in, DXA utilization appears to have slowed and in some reports slightly declined.
To better describe DXA utilization from the initial proposed reduction in 2006 to the actual 
reduction in 2012, as well as update utilization estimates through 2012 we undertook this 
study. We examined the use of DXA by commercially insured younger postmenopausal 
women (aged 50–64) from 2006 through 2012 to determine how DXA utilization had 
changed during this period. Also we investigated the longitudinal use of DXA to determine 
if a specific event or time period where DXA utilization significantly changed.
Methods
We studied a cohort of women aged 50–64 between January 2006 and December 2012 in 
Truven Health Analytics MarketScan® Commercial Claims database. The Marketscan® 
database is a collection of US employer-sponsored health plans, including de-identified 
individual-level clinical utilization, expenditures, and enrollment across inpatient, 
outpatient, prescription drug, and carve-out services with 60 million covered lives in 
2011.(15) The University of North Carolina Institutional Review Board determined that this 
study was exempt.
Women aged 50–64 were selected for this study as they likely comprise the postmenopausal 
population younger than Medicare age who would utilize DXA. DXAs were identified as 
claims with HCPCS (Healthcare Common Procedure Coding System) codes 70675 or 
77080. When two DXA claims were present within 15 days of each other (e.g. one for 
performing the service, and the other for physician interpretation), we aggregated the claims 
as a single DXA claim, based on prior methodology.(11) This study intended to measure 
overall DXA utilization, as such we did not attempt to differentiate between initial and serial 
testing. Women were stratified into 5 year age groups (50–54, 55–59, 60–64) based on age 
from the monthly enrollment file. Utilization was grouped by either month or year as 
specified, women could add multiple DXAs to the numerator and were only required to be 
aged 50 to 64 and enrolled in a health plan for at least one day in the time period to be 
included in the denominator based on previously published methodology.(16) We calculated 
rates of DXA utilization per 1,000 person years (PY) both in aggregate and by 5 year age 
groups, by month and year as specified.
Given that utilization changes were expected during the study period based on prior 
research, we used visual inspection to determine the inflection point in the trend of DXAs. 
From this inspection, July 2009 was determined as the point at which utilization was altered 
and this point was used in our time series models to compare pre- and post-policy 
reimbursements effects on DXA utilization. This point also coincides with a CMS policy 
(CMS-1413-P) which further reduced 2012 reimbursement.(8)
To evaluate the utilization change before and after July 2009 we used segmented linear 
regression.(17, 18) The regression models included a constant term (rate in January 2006), 
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linear time trend (ranging from 1–84 for each month of analyzed data), and a linear time 
trend to assess the changes in slope of the trend line after July 2009 (ranging from 1 [July 
2009] to 41 [December 2012]). Statistical significance was set at p<0.05 a priori. The full 
regression was modeled as:
Autoregressive integrated moving average (ARIMA) models were used to control for 
autocorrelations and seasonality in DXA utilization and conducted using SAS 9.4 (SAS 
Institute, Cary, NC). Our final model did not include a one-time disruption point at July 
2009 as we felt that the change in utilization would be gradual rather than abrupt. When the 
disruption point was used in the models it was not significant and our results were similar.
Results
Seasonally adjusted age stratified DXA utilization per 1,000 PY by month are presented as 
the Figure. In aggregate 451,656 DXAs were performed in 2006, yielding a rate of 144.1 
scans per 1,000 PY, increasing to 148.8 DXAs per 1,000 PY in 2009 before a decline to 
109.7 DXAs per 1,000 PY or 667,982 scans in 2012. Age stratified segmented regression 
results are presented as the Table. DXA utilization in January 2006 for the aggregate 
population was 142.1 DXAs (95% confidence interval [95% CI]: 137.66, 146.92) per 1,000 
PY. If CMS-1413-P had not occurred, yearly DXA utilization was estimated to increase by 
2.24 (95% CI: 0.18, 4.31) per 1,000 PY, however the yearly utilization trend changed to 
−12.98 (95% CI: −17.19, −8.78) DXAs per 1,000 PY in July 2009. Presumably without 
CMS-1413-P we would have expected a rate of 157.98 DXAs per 1,000 PY in December 
2012, however we observed 104.70 DXAs per 1,000 PY a decrease of 53.29 DXAs per 
1,000 PY. These significant reductions were found in aggregate and all three age groups, 
with women aged 60–64 seeing the largest decline.
Discussion
In a commercially insured population of women aged 50–64 we report a decrease of 35 
DXAs per 1,000 PY by year between 2006 and 2012. DXAs were predicted by year to 
increase by 2.24 DXAs per 1,000 PY for the duration of the study, however after further 
reductions in CMS-1413-P (July 2009) utilization decreased by 12.98 DXAs per 1,000 PY. 
Overall, DXA utilization declined between 2006 and 2012.
Our yearly results are similar to those of commercially insured and Medicare beneficiaries 
through 2010. Based on the same database we report a similar magnitude of increase in 
DXA utilization between 2006 and 2009 to O’Malley et al.(14) Our analysis is of women 
aged 50 to 64, however our yearly estimates follow a similar patterns to estimates of both 
Medicare and Medicare supplemental insurance patients. Between 2008 and 2009 where 
O’Malley et al and King et al reported decreases in DXA utilization, Zhang et al reported no 
change, and we report an increase in utilization.(6, 11, 14) We would speculate that these 
differences are due to differing at-risk populations and utilization measures. Additionally, 
our results are not directly comparable to Morden et al as they only report yearly utilization 
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for 2008, 2010, and 2011 and are based on Medicare patients; though their results indicate a 
decrease of 0.4 DXAs per 100 beneficiaries between 2010 and 2011, which are similar to 
our results.(12)
Although we highlight CMS-1413-P, other rationales for decreasing DXA utilization include 
fewer outpatient facilities offering DXAs, lower reimbursement by commercial insurers, 
reduced clinical rationale due to clinical guideline recommendations against routine 
screening in women aged 50 to 64, fewer inappropriate short interval repeat DXAs, as well 
as the possibility that patients may have indicated they would decline treatment regardless of 
the findings of the DXA.(11, 12) It is also possible that the change in utilization after 
CMS-1413P may indicate that at a final rate of ~$45, DXAs were no longer cost effective 
and centers ceased offering them. Overall our results suggest that Medicare DXA 
reimbursement changes may have indirect consequences on commercially insured women 
ages 50–64 even prior to Medicare eligibility.
Our study represents an updated estimate of DXA utilization through 2012, however there 
are limitations. Our results are based on a commercially insured population aged 50 to 64 
who may not be directly comparable to Medicare beneficiaries. We compare our results to 
other studies with differing methodologies, data sources, and study populations which may 
not be directly comparable. Although we highlight the proposal of CMS-1413-P (July 2009) 
as the point where utilization was altered it is likely that other factors as well as other 
policies affected the DXA utilization up to and after this point. We discuss Medicare 
reducing reimbursement for DXAs, which likely affected the reimbursement rates for 
commercial insurance carriers which also may have affected utilization. Reimbursement 
rates for commercial insurers are not publicly available, as such are not discussed in this 
report. The strengths of our analysis include representation of 7 years of data in a large 
commercially insured population as well as segmented regression analysis indicating a time 
period of significant change in utilization after further reimbursement reduction.
As prior research of DXA utilization in a commercial population is only available through 
2009, our study presents updated information on the utilization of DXAs during Medicare 
rate reductions. Also we were able to find and support a specific policy during 
reimbursement changes which was associated with further reduced utilization. Though 
legislative attempts have been made to increase DXA reimbursement rates, the 2014 
reimbursement rate for outpatient DXAs is less than $60, significantly less than before the 
reimbursement cuts and likely below the current cost of performing the test. Reduced DXA 
utilization may be associated with an increase in preventable fractures. As such, follow up 
studies should examine DXA utilization in additional populations and the influence of 
reductions in DXA reimbursement rates on clinical outcomes and associated changes in 
healthcare expenditures.
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Dual energy x-ray absorptiometry (DXA) utilization in woman 50 to 64 years of age per 
1,000 person years by month (2006–2012) with seasonal adjustment
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Table
Predicted yearly impact of additional reimbursement reduction in July 2009 from CMS-1413-P on DXA 




Baseline intercept 119.37 (115.85, 122.88)
Time −0.27 (−0.39, −0.14)
After −12.51 (−12.73, −12.28)
Change −12.77 (−13.03, −12.51)
Age 55–59
Baseline intercept 150.53 (145.74, 155.32)
Time 2.31 (0.15, 4.47)
After −16.29 (−20.10, −12.48)
Change −13.98 (−18.36, −9.60)
Age 60–64
Baseline intercept 166.66 (160.44, 172.88)
Time 4.36 (1.54, 7.18)
After −16.99 (−21.97, −12.02)
Change −12.63 (−18.35, −6.92)
All coefficients are rate per 1,000 person years per year; Baseline intercept is utilization in January 2006; Time is the linear slope of utilization 
prior to July 2009; After is the linear slope of utilization after and including July 2009; Change is the change in slope after July 2009 and is 
calculated as Time + After; All estimates are seasonally adjusted
J Clin Densitom. Author manuscript; available in PMC 2016 April 01.
